• E Alharbi, N Abanmy, A Mullen, S ElAbd, Z Makhzoum, and S Alzahrani.
• Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh Saudi Arabia.
• Niger J Clin Pract. 2024 Aug 1; 27 (8): 965971965-971.

BackgroundType 2 diabetes is a common chronic disease that continues to increase in prevalence globally and is a major healthcare burden. Diabetes and hypertension frequently occur concurrently, and the use of antihypertensive agents is common in diabetic patients. One antihypertensive agent, verapamil, has tentatively shown potentially positive effects on glycemic control in assorted pre-clinical models.AimTo evaluate the effect of verapamil on glycemic control in hypertensive type 2 diabetic patients.MethodsType 2 diabetic hypertensive patients were recruited from King Fahad Medical City, Riyadh, KSA, to receive oral verapamil therapy. Blood pressure and glycometabolic parameters, including fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), C-peptide, and homeostatic model assessment insulin resistance (HOMA-IR), were monitored at baseline and after 6 months of verapamil therapy.ResultsThirty-five patients (16 male, 19 female) with a mean age of 57.2 years were recruited. The use of verapamil was associated with non-significant decreases in HbA1c, FPG, C-peptide, and HOMA-IR. However, a sub-group of 17 participants showed a decrease in HbA1c that was ≥0.5%. Univariate logistic regression showed that baseline BMI, HOMA-IR, and C-peptide were significantly (P < 0.05) associated with HbA1c reductions of ≥0.5%.ConclusionVerapamil is metabolically neutral and allows the stabilization of glycometabolic parameters in type 2 diabetic individuals. Additional research exploring the mechanism behind the variable response to verapamil therapy is warranted.Copyright © 2024 Copyright: © 2024 Nigerian Journal of Clinical Practice.

33 keywords...

hide…